Payment & Shipping Terms:
|Product Name:||Nilotinib||Appearance:||White Crystalline Powder|
|Place Of Origin:||Shaanxi, China||CAS Number::||641571-10-0|
Nilotinib (AMN107, trade name Tasigna), in the form of the hydrochloride monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia. Structurally related to imatinib, it was developed based on the structure of the Abl-imatinib complex to address imatinib intolerance and resistance. Nilotinib is a selective Bcr-Abl tyrosine kinase inhibitor that is 10–30 fold more potent than imatinib in inhibiting Bcr-Abl tyrosine kinase activity and proliferation of Bcr-Abl expressing cells. Nilotinib was developed by Novartis and is sold under the trade name Tasigna.
|Appearance:||White crystalline powder|
Nilotinib is used for treatment of Philadelphia chromosome-positve CML that is refactory or intolerant to prior therapy, including imatinib.